Last updated: August 12, 2026
Salcaprozate sodium, also known as SNAC, is a proprietary oral-delivery excipient rather than a broadly traded commodity excipient. Its commercial value is tied primarily to Novo Nordisk’s oral semaglutide product, Rybelsus. SNAC enables semaglutide absorption in the stomach and is present at 300 mg per Rybelsus tablet. Novo Nordisk does not report SNAC revenue separately, so the excipient’s financial trajectory must be inferred from Rybelsus sales, platform ownership, intellectual-property control and future oral-peptide programs.
Rybelsus generated approximately DKK 20.4 billion in Novo Nordisk sales in 2024, compared with DKK 14.4 billion in 2023, DKK 8.0 billion in 2022 and DKK 2.5 billion in 2021. SNAC’s economic contribution is therefore expanding with the product, but its standalone market value remains undisclosed. Novo Nordisk acquired Emisphere Technologies, SNAC’s original platform owner, in 2020 for approximately $1.8 billion, including assumed debt. The transaction converted Novo from a licensee into the principal owner of the delivery technology and related intellectual property.[1][2]
What is salcaprozate sodium and how is it used?
Salcaprozate sodium is an absorption-enhancing excipient developed through Emisphere Technologies’ Eligen oral-delivery platform. It is also identified as SNAC and has been used to facilitate oral delivery of peptide drugs that would otherwise have poor gastrointestinal absorption.
In Rybelsus, SNAC performs several delivery functions:
- It locally increases gastric pH.
- It helps protect semaglutide from enzymatic degradation.
- It promotes absorption across the gastric epithelium.
- It supports delivery of semaglutide before significant intestinal transit.
The commercial formulation contains semaglutide and 300 mg of SNAC per tablet. SNAC is therefore used at a substantially higher mass than the active pharmaceutical ingredient. This increases the volume, manufacturing and supply-chain significance of the excipient relative to conventional low-dose formulation ingredients.[3]
SNAC is not equivalent to a standard high-volume excipient such as microcrystalline cellulose, lactose or magnesium stearate. It is a functional delivery component with platform-specific performance requirements. Substitution would likely require reformulation, comparative pharmacokinetic studies and regulatory review.
What is the current market size for salcaprozate sodium?
No reliable public source reports a standalone global market size for salcaprozate sodium. Market-research reports that aggregate oral drug-delivery excipients, permeation enhancers or pharmaceutical excipients do not isolate SNAC sales in a verifiable manner.
The addressable SNAC market is better measured through Rybelsus tablet volumes. Novo Nordisk reports product sales, but not SNAC consumption, transfer prices or gross profit by excipient. The commercial calculation is straightforward:
| Metric |
Publicly disclosed position |
| SNAC per Rybelsus tablet |
300 mg |
| Primary marketed product |
Rybelsus |
| Rybelsus 2021 sales |
Approximately DKK 2.5 billion |
| Rybelsus 2022 sales |
Approximately DKK 8.0 billion |
| Rybelsus 2023 sales |
Approximately DKK 14.4 billion |
| Rybelsus 2024 sales |
Approximately DKK 20.4 billion |
| Standalone SNAC revenue |
Not disclosed |
| Publicly identified broad multi-customer SNAC market |
Not established |
Rybelsus sales growth does not equal SNAC revenue growth. The value of SNAC depends on tablet volume, internal manufacturing economics, procurement costs, transfer-pricing arrangements and whether Novo Nordisk uses SNAC in future products.
How has the financial trajectory of SNAC developed?
SNAC’s financial trajectory has passed through three stages.
Platform development and licensing
Emisphere developed the Eligen platform and licensed technology to pharmaceutical companies, including Novo Nordisk. In this period, SNAC had option value based on the possibility of enabling oral delivery of biologics and peptides. Revenue was primarily linked to licensing, development payments and potential royalties rather than large-scale excipient sales.
Commercial validation through Rybelsus
Rybelsus received U.S. Food and Drug Administration approval in September 2019 for adults with type 2 diabetes as an adjunct to diet and exercise.[3] This created the first major commercial validation of SNAC in a marketed oral peptide product.
The product’s sales trajectory was rapid:
| Fiscal year |
Rybelsus sales |
Year-over-year change |
| 2021 |
DKK 2.5 billion |
Not comparable to 2020 launch base |
| 2022 |
DKK 8.0 billion |
Approximately 216% |
| 2023 |
DKK 14.4 billion |
Approximately 79% |
| 2024 |
DKK 20.4 billion |
Approximately 42% |
The sales increase supports higher SNAC consumption, stronger manufacturing scale and greater strategic value for the delivery platform. It does not establish the amount paid to SNAC suppliers or the excipient’s margin.
Vertical integration by Novo Nordisk
Novo Nordisk agreed to acquire Emisphere in 2020. The transaction gave Novo Nordisk control of the Eligen technology, including rights related to oral semaglutide and other oral-delivery applications.[1] This materially changed SNAC’s economic structure.
Before the acquisition, SNAC could have generated external licensing revenue for Emisphere. After the acquisition, much of the economic value shifted into Novo Nordisk’s internal product economics, intellectual-property position and pipeline optionality. The transaction reduced the likelihood of a transparent third-party SNAC market because the principal commercial user also controls the platform owner.
What companies manufacture or supply salcaprozate sodium?
Public disclosures do not establish a complete list of commercial SNAC manufacturers, approved suppliers or annual production volumes. Novo Nordisk has not publicly identified SNAC as a separately reported supplier category in its financial statements.
The supply chain has several potential control points:
- Manufacture of salcaprozate sodium to pharmaceutical-grade specifications.
- Analytical testing for identity, purity, residual solvents and impurities.
- Particle-size and physical-property control.
- Integration into the Rybelsus tablet formulation.
- Finished-product manufacturing under Novo Nordisk quality systems.
SNAC’s strategic importance makes supplier qualification more demanding than for ordinary excipients. A supplier change could require comparability work, process validation and regulatory assessment, particularly if the change affects dissolution, gastric performance or semaglutide exposure.
What patents protect salcaprozate sodium and oral semaglutide formulations?
SNAC protection is likely to arise from several overlapping categories rather than a single composition-of-matter patent:
- Composition and salt-form patents for salcaprozate sodium.
- Oral-delivery platform patents covering absorption enhancers and active-agent complexes.
- Formulation patents covering semaglutide, SNAC and tablet composition.
- Manufacturing patents covering tablet preparation and drug-excipient processing.
- Method-of-use patents covering oral semaglutide treatment.
- Regulatory exclusivity associated with the approved product.
The commercial barrier is therefore the combined estate around Rybelsus, not merely the chemical identity of SNAC. A competitor could potentially obtain SNAC or develop a different permeation enhancer, but it would still need to demonstrate bioequivalence or clinical equivalence for the complete oral product.
Exact patent scope, expiration dates and Orange Book status must be evaluated at the product level. The FDA Orange Book lists patents and exclusivity associated with approved drug products, while it does not create a standalone listing for SNAC as an excipient.[4]
When does SNAC lose exclusivity?
SNAC has no single market-wide loss-of-exclusivity date. Different rights may expire at different times across jurisdictions and patent families.
For Rybelsus, market-entry timing depends on:
- Expiration of listed U.S. patents.
- Any patent-term extension or pediatric exclusivity.
- Regulatory exclusivity.
- The outcome of Paragraph IV litigation.
- Whether a generic applicant can design around the formulation or delivery patents.
- Whether the generic can establish the required pharmacokinetic relationship.
The practical exclusivity period for SNAC is therefore linked to the earliest commercially meaningful opportunity to launch a competing oral semaglutide product. A patent covering SNAC alone would not necessarily remove Rybelsus protection if formulation, method-of-use or manufacturing patents remain enforceable.
Are there Paragraph IV challenges to SNAC or Rybelsus?
A Paragraph IV challenge would target listed Rybelsus patents through an abbreviated new drug application. The challenge would normally address the finished drug product, not SNAC as a standalone excipient.
Potential legal theories include:
- Invalidity based on obviousness or lack of written description.
- Noninfringement through a different formulation.
- Failure of the listed patent to cover the proposed generic product.
- Challenges to crystalline, tablet or manufacturing claims.
- Challenges to method-of-use claims.
Publicly available FDA and court records should be used to determine whether a specific ANDA filer has submitted a Paragraph IV certification and whether litigation has triggered a 30-month stay. A general SNAC market analysis cannot treat every oral-semaglutide patent dispute as an SNAC dispute.
No broad biosimilar pathway applies to SNAC. SNAC is a small-molecule excipient, and Rybelsus is a chemically manufactured tablet, not a biologic. Competitive entry would use the generic-drug pathway rather than the biosimilar pathway.
What is the FDA regulatory status of SNAC?
SNAC is not marketed by itself as an approved therapeutic drug. Its regulatory relevance comes from its use in the approved Rybelsus drug product.
The FDA-approved Rybelsus label identifies SNAC as an inactive ingredient and specifies its quantity in each tablet.[3] This status differs from an independent FDA approval for SNAC. The excipient’s use is supported by the safety, quality and clinical performance package for the finished product.
SNAC’s regulatory value is high because its function is linked to semaglutide exposure. Changes to the excipient grade, supplier, manufacturing process or formulation could affect product performance and require regulatory documentation.
How strong is the commercial and patent position for SNAC?
SNAC has a strong commercial position in the near term because:
- Rybelsus has generated rapidly increasing sales.
- SNAC is integrated into the approved tablet formulation.
- Novo Nordisk owns the original platform company.
- Oral peptide delivery remains strategically important.
- Substitution would require product-specific development and regulatory work.
The position is weaker in other respects:
- Standalone SNAC revenue is not disclosed.
- The commercial market is highly concentrated.
- Future oral products may use different delivery technologies.
- Rybelsus faces eventual generic and patent challenges.
- The value of SNAC depends heavily on Novo Nordisk’s pipeline decisions.
SNAC is therefore a high-value, low-transparency excipient asset. Its economics resemble a controlled drug-delivery platform more than a conventional bulk ingredient.
How does SNAC compare with competing oral-delivery technologies?
| Technology category |
Commercial status |
Key advantage |
Main constraint |
| SNAC |
Commercial in Rybelsus |
Demonstrated oral peptide delivery |
Dependence on one major product |
| Sodium caprate and related permeation enhancers |
Used in development programs |
Established intestinal absorption rationale |
Variable tolerability and exposure |
| Self-emulsifying systems |
Used in small molecules and some peptides |
Can improve solubilization |
Complex formulation and scale-up |
| Mucoadhesive systems |
Development-stage use |
May increase residence time |
Inconsistent clinical performance |
| Nanoparticle and carrier systems |
Broad research activity |
Potential protection and targeting |
Manufacturing and regulatory complexity |
| Injectable peptide delivery |
Commercial standard |
High and predictable exposure |
Administration burden |
SNAC’s primary competitive advantage is regulatory and clinical validation. Many oral-delivery technologies have attractive laboratory data, but few have supported a high-volume commercial peptide tablet.
What generic launch risks exist for Rybelsus and SNAC?
Generic entry risk is moderate over the medium term and increases as key patents expire or are invalidated. The main obstacles are formulation complexity and the need to reproduce semaglutide exposure using a delivery system that may be sensitive to SNAC concentration, tablet architecture and administration conditions.
A generic launch could follow several routes:
- A product that directly copies the SNAC-containing formulation, subject to patent clearance.
- A formulation using a different absorption enhancer.
- A product that challenges formulation and method-of-use patents.
- A later-entry product launched after settlement or patent expiry.
The highest-risk scenario for Novo Nordisk is simultaneous loss of several formulation and method-of-use barriers combined with continued demand for lower-priced oral GLP-1 therapy. The highest-risk scenario for SNAC suppliers is loss of Rybelsus volume rather than substitution of SNAC in another product.
What licensing deals affect salcaprozate sodium?
The most important disclosed transaction is Novo Nordisk’s acquisition of Emisphere Technologies in 2020. Before that deal, Novo Nordisk had licensed Emisphere’s Eligen technology for oral semaglutide development. The acquisition consolidated ownership of the technology, rights and associated obligations within Novo Nordisk.[1]
No major independent SNAC licensing portfolio has been publicly established after the acquisition. This reduces external licensing visibility but increases Novo Nordisk’s ability to deploy SNAC selectively in future oral peptide products.
What is the outlook for SNAC revenue and valuation?
SNAC’s near-term outlook is positive because Rybelsus sales continue to grow. Its longer-term trajectory depends on four variables:
- Rybelsus unit growth.
- The timing of generic entry.
- Expansion of SNAC into additional Novo Nordisk products.
- Continued protection of formulation and delivery intellectual property.
The value of SNAC should not be calculated as a fixed percentage of Rybelsus sales without proprietary transfer-price and cost data. A more defensible valuation framework treats SNAC as a strategic input with three components:
| Value component |
Financial relevance |
| Current excipient consumption |
Linked to Rybelsus tablet volume |
| Manufacturing margin |
Depends on internal cost and supplier economics |
| Platform option value |
Depends on future oral peptide products |
| IP and regulatory replacement cost |
Raises switching barriers |
| Exclusivity duration |
Determines how long SNAC captures protected demand |
The strongest measurable indicator is Rybelsus revenue growth. The strongest qualitative indicator is Novo Nordisk’s ownership of the delivery platform. The least observable variable is SNAC’s standalone margin.
Key Takeaways
- Salcaprozate sodium, or SNAC, is a proprietary oral-delivery excipient used in Rybelsus.
- Each Rybelsus tablet contains 300 mg of SNAC.
- Rybelsus sales increased from approximately DKK 2.5 billion in 2021 to DKK 20.4 billion in 2024.
- Novo Nordisk does not disclose SNAC revenue, volume, pricing or margin separately.
- Novo Nordisk acquired Emisphere Technologies in 2020 for approximately $1.8 billion, consolidating control of the Eligen platform.
- SNAC has no standalone biosimilar pathway or independent Orange Book product listing.
- Generic risk will depend on Rybelsus formulation, method-of-use, manufacturing and delivery patents.
- SNAC’s commercial position is strong but concentrated, with Rybelsus representing the principal disclosed commercial application.
- Future value depends on oral peptide pipeline expansion and the duration of Rybelsus market protection.
FAQs
Is salcaprozate sodium the same as SNAC?
Yes. Salcaprozate sodium is commonly abbreviated as SNAC and is the principal absorption-enhancing excipient used in Rybelsus.
How much SNAC is in Rybelsus?
Each Rybelsus tablet contains 300 mg of salcaprozate sodium, according to the FDA prescribing information.[3]
Does SNAC have its own pharmaceutical market?
SNAC does not have a transparent standalone market comparable with conventional excipients. Its principal disclosed commercial value is tied to Rybelsus and Novo Nordisk’s oral-delivery platform.
Can another company replace SNAC in Rybelsus?
A replacement would require a reformulated product and regulatory support demonstrating acceptable semaglutide exposure, safety, quality and clinical performance. Patent clearance would also be required.
Is SNAC relevant to biosimilar competition?
No. SNAC is a small-molecule excipient used in a chemically manufactured tablet. Competition against Rybelsus would generally proceed through the generic-drug pathway, not the biosimilar pathway.
References
-
Novo Nordisk A/S. (2020, October 27). Novo Nordisk to acquire Emisphere Technologies and its Eligen technology. Novo Nordisk investor communication.
-
Novo Nordisk A/S. (2025). Annual report 2024. Novo Nordisk.
-
U.S. Food and Drug Administration. (2024). Rybelsus (semaglutide) tablets: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
